Inventor · disambiguated record
Charles Theuer
Also filed as: THEUER CHARLES · THEUER CHARLES P
10 granted patents·11 pending applications·103 citations·filing 2007–2019
90Inventor score
Files withTRACON PHARMACEUTICALS INC16THEUER CHARLES3THEUER CHARLES P1TRACON PHARMACEUTICALS INC A D1
Top patents by PatentIndex Score
21 records- 0194US9926375B2Anti-endoglin antibodies and uses thereofTRACON PHARMACEUTICALS INC·Filed 2016·Granted Mar 27, 2018·15 cites·16 claims
- 0294US8221753B2Endoglin antibodiesTHEUER CHARLES·Filed 2010·Granted Jul 17, 2012·31 cites·6 claims
- 0393US9150652B2Endoglin antibodiesTRACON PHARMACEUTICALS INC·Filed 2013·Granted Oct 6, 2015·18 cites·24 claims
- 0491US9944714B2Endoglin antibodiesTRACON PHARMACEUTICALS INC·Filed 2016·Granted Apr 17, 2018·7 cites·29 claims
- 0591US8609094B2Endoglin antibodiesTHEUER CHARLES·Filed 2012·Granted Dec 17, 2013·14 cites·14 claims
- 0688US10336831B2Use of anti-endoglin antibodies for treating ocular fibrosisTRACON PHARMACEUTICALS INC·Filed 2018·Granted Jul 2, 2019·6 cites·20 claims
- 0788US9518122B2Endoglin antibodiesTRACON PHARMACEUTICALS INC·Filed 2015·Granted Dec 13, 2016·5 cites·24 claims
- 0887US10155820B2Anti-endoglin antibodies and uses thereofTRACON PHARMACEUTICALS INC·Filed 2015·Granted Dec 18, 2018·6 cites·22 claims
- 0969US10195281B2Antibody formulations and uses thereofTRACON PHARMACEUTICALS INC·Filed 2013·Granted Feb 5, 2019·1 cites·36 claims
- 1069US2020048360A1Endoglin AntibodiesTRACON PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1165US2018194854A1Endoglin AntibodiesTRACON PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1260US2010098692A1Humanized Endoglin AntibodiesTRACON PHARMACEUTICALS INC A D·Filed 2009·Application pending·0 cites
- 1358US2020087389A1Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agentsTRACON PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1457US8017618B2Antifolate agent combinations in the treatment of cancerTRACON PHARMACEUTICALS INC·Filed 2007·Granted Sep 13, 2011·0 cites·36 claims
- 1556US2019016815A1Anti-endoglin antibodies and uses thereofTRACON PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1655US2018371072A1Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agentsTRACON PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1755US2017312233A1Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitorsTRACON PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 1849US2018311359A1Antibody Formulations and Uses ThereofTRACON PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1948US2012244147A1Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agentsTHEUER CHARLES P·Filed 2010·Application pending·0 cites
- 2044US2013030237A1Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitorsTHEUER CHARLES·Filed 2011·Application pending·0 cites
- 2143US2018057602A1Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agentsTRACON PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Charles Theuer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →